A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]

Squamous Non-Small Cell Lung Cancer Clinical Trial

Official title:

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel or Atezolizumab in Combination With Carboplatin+Nab-Paclitaxel Versus Carboplatin+Nab-Paclitaxel in Chemotherapy-Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02367794
• Other study ID #: GO29437
• Secondary ID: 2014-003208-59
• Status: Completed
• Phase: Phase 3
• Start date: June 11, 2015
• Est. completion date: February 17, 2021

Study information

• Verified date: March 2022
• Source: Hoffmann-La Roche
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel compared with treatment with carboplatin + nab-paclitaxel in chemotherapy-naive participants with Stage IV squamous NSCLC.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1021
• Est. completion date: February 17, 2021
• Est. primary completion date: October 3, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• Histologically or cytologically confirmed, treatment-naïve Stage IV squamous NSCLC
• Previously obtained archival tumor tissue or tissue obtained from biopsy at screening
• Measurable disease as defined by RECIST v1.1
• Adequate hematologic and end organ function

Exclusion Criteria:

• Active or untreated central nervous system (CNS) metastasis
• Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
• Pregnant or lactating women
• History of autoimmune disease
• History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest Computed Tomography (CT) scan, History of radiation pneumonitis in the radiation field (fibrosis) is permitted
• Positive test for Human Immunodeficiency Virus (HIV)
• Active hepatitis B or hepatitis C
• Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies, anti-programmed death-1 (anti-PD-1), and anti-PD-L1 therapeutic antibody
• Severe infection within 4 weeks prior to randomization
• Significant history of cardiovascular disease

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Squamous Non-Small Cell Lung Cancer

Intervention

Drug:
• Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody
Atezolizumab 1200 milligrams (mg) intravenous infusion (IV) on day 1 of each 21-day cycle.
• Carboplatin
Carboplatin area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles.
• Nab-Paclitaxel
Nab-paclitaxel 100 milligrams per meter squared (mg/m^2) IV on Day 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles.
• Paclitaxel
Paclitaxel 200 mg/m^2 IV on Day 1 of each 21-day cycle for 4 or 6 cycles. Participants of Asian race/ethnicity will be administered paclitaxel 175 mg/m^2 IV.

Locations

Country	Name	City	State
Argentina	Fundación CENIT para la Investigación en Neurociencias	Buenos Aires
Argentina	Sanatorio Allende	Cordoba
Argentina	Centro Oncologico Riojano Integral (CORI)	La Rioja
Argentina	Clínica Pergamino	Pergamino
Argentina	Fundacion Koriza	Santa Rosa
Argentina	Centro de Investigacion; Clinica - Clinica Viedma S.A.	Viedma
Australia	Royal Adelaide Hospital	Adelaide	South Australia
Australia	Chris O'Brien Lifehouse	Camperdown	New South Wales
Australia	Prince Charles Hospital	Chermside	Queensland
Australia	Austin Health	Heidelberg	Victoria
Australia	Cabrini Hospital Malvern	Malvern	Victoria
Australia	Sir Charles Gairdner Hospital	Nedlands	Western Australia
Australia	Sunshine Hospital	St Albans	Victoria
Australia	Townsville Hospital	Townsville	Queensland
Australia	Calvary Mater Newcastle; Medical Oncology	Waratah	New South Wales
Australia	Princess Alexandra Hospital	Woolloongabba	Queensland
Austria	Paracelsus Medizinische Privatuniversität	Salzburg
Belgium	Cliniques Universitaires St-Luc	Bruxelles
Belgium	CHU Sart-Tilman	Liège
Belgium	Clinique Ste-Elisabeth	Namur
Belgium	Werken Glorieux VZW	Ronse
Belgium	GasthuisZusters Antwerpen	Wilrijk
Brazil	*X*Fundação Pio XII Hospital de Câncer de Barretos	Barretos	SP
Brazil	Cenantron - Centro Avancado de Tratamento Oncologico	Belo Horizonte	MG
Brazil	IPCEM; Instituto de Pesquisa de Estudos Multicêntricos	Caxias do Sul	RS
Brazil	Hospital Bruno Born	Lajeado	RS
Brazil	Instituto Do Cancer Delondrina_X; Unidade De Pesquisa Clinica	Londrina	PR
Brazil	Liga Norte Riograndense Contra O Câncer	Natal	RN
Brazil	Hospital das Clinicas - UFRGS	Porto Alegre	RS
Brazil	Hospital Mae de Deus	Porto Alegre	RS
Brazil	Hospital de Base de Sao Jose do Rio Preto	Sao Jose do Rio Preto	SP
Brazil	Hospital Do Cancer A C Camargo	Sao Paulo	SP
Bulgaria	Multiprofile Hospital for Active Treatment Central Onco Hospital OOD	Plovdiv
Bulgaria	Multiprofile Hospital for Active Treatment Serdika EOOD	Sofia
Canada	Royal Victoria Regional Health Centre	Barrie	Ontario
Canada	William Osler Health Centre	Etobicoke	Ontario
Canada	Cite de La Sante de Laval; Hemato-Oncologie	Laval	Quebec
Canada	Hôpital du Sacré-Coeur de Montreal	Montreal	Quebec
Canada	Lakeridge Health Center	Oshawa	Ontario
Canada	St. Jerome Medical Research	St. Jerome	Quebec
Chile	Health & Care SPA	Santiago
Chile	Sociedad de Investigaciones Medicas Ltda (SIM)	Temuco
France	CHU de Grenoble	Grenoble
France	Ctr Jean Bernard Clin V. Hugo; Service d'Oncologie Méd	Le Mans
France	Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes	Lyon
France	Clinique Clémentville	Montpellier
France	Hopital de La Source	Orleans
France	Centre Hospitalier Lyon Sud	Pierre Benite
France	Hopital de Pontchaillou; Service de Pneumologie	Rennes
France	Centre Hospitalier Regional Sud Reunion; Service de Pneumologie	Saint Pierre
France	CH de Saint Quentin	Saint Quentin
France	Hôpital d'Instruction des Armées de Sainte Anne; Service Pharmacie Essais Cliniques	Toulon Cedex 9
Germany	Charite - Universitätsmedizin Berlin	Berlin
Germany	Ev.Krankenhaus Bielefeld gGmbH; Klinik für Innere Medizin und Geriatrie	Bielefeld
Germany	Augusta Kranken-Anstalt gGmbH	Bochum
Germany	Universitätsklinikum "Carl Gustav Carus" der Technischen Universität Dresden	Dresden
Germany	St. Elisabethen Krankenhaus	Frankfurt am Main
Germany	Robert Bosch Krankenhaus; Pneumologie und pneumologische Onkologie	Gerlingen
Germany	LungenClinic Großhansdorf GmbH	Großhansdorf
Germany	Krankenhaus Martha-Maria; Halle-Dolau gGmbH	Halle
Germany	Asklepios Klinik Harburg	Hamburg
Germany	Universitätsklinikum Hamburg-Eppendorf	Hamburg
Germany	Lungenklinik Hemer	Hemer
Germany	Universität Des Saarlandes; Klinik für Innere Medizin V	Homburg
Germany	Fachklinik für Lungenerkrankungen	Immenhausen
Germany	Kliniken der Stadt Koln gGmbH	Koln
Germany	Johannes Wesling Klinikum Minden; Hämatologie, Onkologie, Hämostaseologie und Palliativmedizin	Minden
Germany	Klinikum Bogenhausen; Klinik für Pneumologie und Pneumologische Onkologie	München
Germany	Klinikum der Universität Regensburg	Regensburg
Germany	Krankenhaus Barmherzige Bruder Regensburg	Regensburg
Germany	Stiftung Mathias-Spital Rheine	Rheine
Germany	Schwarzwald-Baar Klinikum/VS GmbH; Onkologie/Hämatologie/Infektologie	Villingen-Schwenningen
Israel	Soroka Medical Center	Beer Sheva
Israel	Hadassah University Hospital - Ein Kerem	Jerusalem
Israel	Meir Medical Center; Oncology	Kfar-Saba
Israel	Rabin Medical Center	Petach Tiqwa
Israel	Chaim Sheba Medical Center; Oncology Dept	Ramat Gan
Israel	Rambam Health Corporation; Oncology Institute	Rambam
Israel	Tel Aviv Sourasky Medical Ctr; Oncology	Tel Aviv
Italy	Azienda Ospedaliera di Rilievo Nazionale e di Alta Specialita San Giuseppe Moscati	Avellino	Campania
Italy	IRCCS Giovanni Paolo II Istituto Oncologico	Bari	Puglia
Italy	Policlinico Vittorio Emanuele	Catania	Sicilia
Italy	ASL 3 Genovese; DSM	Genova	Liguria
Italy	Ospedale Civile - Livorno	Livorno	Toscana
Italy	AORN A Cardarelli	Napoli	Campania
Italy	Azienda Ospedaliero Universitaria Seconda Università degli Studi di Napoli; Farmacia Centralizzata	Napoli	Campania
Italy	Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale	Napoli	Campania
Italy	Fondazione IRCCS Policlinico San Matteo	Pavia	Lombardia
Italy	Ospedale Silvestrini	Perugia	Umbria
Italy	Azienda Ospedaliero Universitaria Pisana	Pisa	Toscana
Italy	Azienda Ospedaliera San Camillo Forlanini	Roma	Lazio
Japan	Aichi Cancer Center Hospital; Respiratory Medicine	Aichi
Japan	Nagoya University Hospital; Respiratory Medicine	Aichi
Japan	National Cancer Center Hospital East; Thoracic Oncology	Chiba
Japan	National Hospital Organization Shikoku Cancer Center; Internal Medicine	Ehime
Japan	Kyushu University Hospital; Respiratory	Fukuoka
Japan	National Hospital Organization Kyushu Medical Center; Respiratory Internal Medicine	Fukuoka
Japan	Hyogo Cancer Center; Thoracic Oncology	Hyogo
Japan	Kobe City Medical Center General Hospital; Respiratory Medicine	Hyogo
Japan	National Hospital Organization Himeji Medical Center	Hyogo
Japan	Ibaraki Prefectural Central Hospital; Division of respiratory	Ibaraki
Japan	Kanagawa Cancer Center;Thoracic Oncology	Kanagawa
Japan	Kyoto University Hospital, Respiratory Medicine	Kyoto
Japan	Sendai Kousei Hospital; Pulmonary Medicine	Miyagi
Japan	Niigata University Medical & Dental Hospital; Respiratory Medicine and Infectious Disease	Niigata
Japan	Okayama University Hospital; Respiratory and Allergy Medicine	Okayama
Japan	Kansai Medical university Hospital; Thoracic Oncology	Osaka
Japan	Osaka City Uni Hospital; Respiratory Medicine	Osaka
Japan	Osaka Habikino Medical Center	Osaka
Japan	Osaka International Cancer Institute; Thoracic Oncology	Osaka
Japan	National Hospital Organization Kinki-Chuo Chest Medical Center	Sakai-shi
Japan	Saitama Cancer Center; Thoracic Oncology	Satima
Japan	Shizuoka Cancer Center; Thoracic Oncology	Shizuoka
Japan	National Cancer Center Hospital; Thoracic Medical Oncology	Tokyo
Japan	Tokyo Medical University Hospital; Dept of Surgery	Tokyo
Latvia	Pauls Stradins Clinical University Hospital	Riga
Latvia	Riga East Clinical University Hospital Latvian Oncology Centre	Riga
Lithuania	National Cancer Institute	Vilnius
Mexico	Centro Universitario Contra El Cancer	Monterrey
Mexico	Cancerología	Queretaro
Netherlands	Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis	Amsterdam
Netherlands	VU Medisch Centrum; VU University Medical Center	Amsterdam
Netherlands	Ziekenhuis Gelderse Vallei	EDE
Netherlands	Catharina Hospital; Afdeling Longgeneeskunde en Tuberculose	Eindhoven
Netherlands	St. Antonius Ziekenhuis; R&D Long	Nieuwegein
Peru	Centro Medico Monte Carmelo	Arequipa
Peru	Hospital Nacional Guillermo Almenara Irigoyen ESSALUD	Lima
Peru	Instituto Regional de Enfermedades Neoplásicas Del Norte	Trujillo
Portugal	Hospital Pulido Valente; Servico de Pneumologia	Lisboa
Portugal	IPO de Lisboa; Servico de Pneumologia	Lisboa
Portugal	Centro Hospitalar do Porto - Hospital de Santo António	Porto
Portugal	Hospital de Sao Joao; Servico de Pneumologia	Porto
Portugal	Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe	Porto
Russian Federation	Moscow City Oncology Hospital #62	Moscovskaya Oblast	Moskovskaja Oblast
Russian Federation	Russian Oncology Research Center n.a. N.N. Blokhin	Moscow
Russian Federation	Clinical Oncology Dispensary	Omsk
Russian Federation	City Clinical Oncology Dispensary	Saint-Petersburg
Russian Federation	Volgograd Regional Clinical Oncology Dispensary	Volgograd
Singapore	National Cancer Centre	Singapore
Singapore	National University Hospital	Singapore
Slovakia	Narodny onkologicky ustav	Bratislava
Slovakia	Univerzitna nemocnica Bratislava	Bratislava
Slovakia	POKO Poprad s.r.o.	Poprad
Spain	Complejo Hospitalario Universitario A Coruña	A Coruña	LA Coruña
Spain	Hospital Clinic de Barcelona	Barcelona
Spain	Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia	Barcelona
Spain	Hospital del Mar	Barcelona
Spain	Hospital Univ Vall d'Hebron; Servicio de Oncologia	Barcelona
Spain	Hospital Universitario Reina Sofia	Cordoba
Spain	Instituto Catalan de Oncologia de Hospitalet (ICO); Servicio de Farmacia	L'Hospitalet de Llobregat	Barcelona
Spain	Complejo Hospitalario Universitario Insular-Materno Infantil	Las Palmas de Gran Canaria	LAS Palmas
Spain	Hospital Lucus Augusti; Servicio de Oncologia	Lugo
Spain	Fundación Jimenez Díaz	Madrid
Spain	Hospital Clinico San Carlos; Servicio de Oncologia	Madrid
Spain	HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia	Madrid
Spain	Hospital General Universitario Gregorio Marañon; Servicio de Oncologia	Madrid
Spain	Hospital Ramon y Cajal; Servicio de Oncologia	Madrid
Spain	Hospital Universitario 12 de Octubre	Madrid
Spain	Hospital Universitario La Paz	Madrid
Spain	Hospital Universitario Son Espases	Palma De Mallorca	Islas Baleares
Spain	Hospital Universitario de Canarias	S. Cristobal De La Laguna	Tenerife
Spain	Corporacio Sanitaria Parc Tauli; Servicio de Oncologia	Sabadell	Barcelona
Spain	Hospital Universitario Marques de Valdecilla; Servicio de Oncologia	Santander	Cantabria
Spain	Hospital Nuestra Senora de Valme	Seville	Sevilla
Spain	Hospital Clinico Universitario de Valencia	Valencia
Spain	Hospital General Universitario de Valencia	Valencia
Spain	Hospital Universitario Miguel Servet	Zaragoza
Taiwan	Changhua Christian Hospital; Hematology-Oncology	Changhua
Taiwan	Kaohsiung Medical University Hospital; Department of Urology	Kaohsiung City
Taiwan	Chi Mei Medical Center Liou Ying Campus	Liuying Township
Taiwan	Chang Gung Memorial Hospital Chiayi	Putzu
Taiwan	China Medical University Hospital	Taichung
Taiwan	Mackay Memorial Hospital	Taipei
Taiwan	National Taiwan Uni Hospital	Taipei City
Ukraine	Municipal Institution Chernivtsi Regional Clinical Oncology Dispensary; Surgery Department #1	Chernivtsi
Ukraine	Municipal Institution City Clinical Hospital #4 of Dnipro City Council - PPDS; Dept of Chemotherapy	Dnipropetrovsk	Katerynoslav Governorate
Ukraine	Communal Non profit Enterprise Regional Center of Oncology; Oncosurgical dept of thoracic organs	Kharkiv	Kharkiv Governorate
Ukraine	SI Institute of Medical Radiology n.a. S.P. Hryhoriev of NAMS of Ukraine	Kharkiv
Ukraine	ME Kryviy Rih Oncology Dispensary of Dnipropetrovs'k Regional Council; Chemotherapy Department	Kryvyi Rih
Ukraine	MI of the Lviv Regional Council Lviv Oncology Regional Treatment and Diagnostic Centre; Chemotherapy	Lviv	Volhynian Governorate
Ukraine	Poltava Regional Clinical Oncology Dispensary of Poltava Regional Council; Thoracic department	Poltava
Ukraine	Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary	Sumy
Ukraine	Uzhgorod Central City Clinical Hospital	Uzhhorod	Katerynoslav Governorate
Ukraine	Communal Nonprofit Enterprise Podilsky Regional Center Of Oncology OfTheVinnytsia Regional Council	Vinnytsia	KIEV Governorate
Ukraine	MNPE Zaporizhzhia Regional Antitumor Center ZRC	Zaporizhzhia	Katerynoslav Governorate
United States	St. Joseph Mercy Health System	Ann Arbor	Michigan
United States	University Cancer & Blood Center, LLC; Research	Athens	Georgia
United States	Southern CA Permanente Med Grp	Bellflower	California
United States	St. Luke's Cancer Care Associates	Bethlehem	Pennsylvania
United States	Hematology-Oncology; Associates of the Quad Cities	Bettendorf	Iowa
United States	Billings Clinic	Billings	Montana
United States	Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital	Carrollton	Georgia
United States	Ironwood Cancer & Research Centers	Chandler	Arizona
United States	SCRI Tennessee Oncology Chattanooga	Chattanooga	Tennessee
United States	University of Chicago	Chicago	Illinois
United States	University of Cincinnati	Cincinnati	Ohio
United States	Mark H. Zangmeister Center	Columbus	Ohio
United States	Danbury Hospital	Danbury	Connecticut
United States	SCRI The Center For Cancer and Blood Disorders	Denton	Texas
United States	Rocky Mountain Cancer Center	Denver	Colorado
United States	Karmanos Cancer Institute	Detroit	Michigan
United States	St. Luke's Regional Cancer Center	Duluth	Minnesota
United States	Providence Regional Cancer Partnership	Everett	Washington
United States	Virginia Cancer Specialists, PC	Fairfax	Virginia
United States	Southcoast Health System; Southcoast Centers For Cancer Care	Fairhaven	Massachusetts
United States	Holy Cross Hospital Inc	Fort Lauderdale	Florida
United States	SCRI Florida Cancer Specialists South	Fort Myers	Florida
United States	Fort Wayne Med Oncology & Hematology Inc	Fort Wayne	Indiana
United States	Maryland Oncology Hematology (Lanham) - USOR	Gettysburg	Pennsylvania
United States	Oncology Hematology Care, Inc.	Hamilton	Ohio
United States	Joliet Oncology-Hematology; Associates, Ltd.	Joliet	Illinois
United States	Tennessee Cancer Specialists	Knoxville	Tennessee
United States	Lahey Clinic Med Ctr	Lexington	Kentucky
United States	Longview Cancer Center	Longview	Texas
United States	Norton Cancer Institute	Louisville	Kentucky
United States	Central Georgia Cancer Care PC	Macon	Georgia
United States	Ochsner Clinic Foundation	New Orleans	Louisiana
United States	Southeastern Regional Medical Center, Inc.	Newnan	Georgia
United States	Virginia Oncology Associates	Norfolk	Virginia
United States	Kaiser Permanente Oakland Medical Center	Oakland	California
United States	Florida Cancer Specialists	Palm Beach Gardens	Florida
United States	Valley Hospital; Oncology Research	Paramus	New Jersey
United States	Allegheny Cancer Center	Pittsburgh	Pennsylvania
United States	Univ of Pittsburgh Medical Ctr	Pittsburgh	Pennsylvania
United States	Hematology Oncology Associates of the Treasure Coast	Port Saint Lucie	Florida
United States	Oregon Health & Science Uni	Portland	Oregon
United States	Quincy Medical Group	Quincy	Illinois
United States	Blue Ridge Cancer Care	Roanoke	Virginia
United States	Kaiser Permanente - Sacramento Medical Center and Medical Offices	Sacramento	California
United States	Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building)	Saint Petersburg	Florida
United States	W.G. Bill Hefner VA Medical Center	Salisbury	North Carolina
United States	Kaiser Permanente - San Leandro Medical Center	San Leandro	California
United States	Kaiser Permanente - Santa Clara	Santa Clara	California
United States	New England Cancer Specialists	Scarborough	Maine
United States	Regional Cancer Care Associates LLC	Sewell	New Jersey
United States	Siouxland Hematology/Oncology	Sioux City	Iowa
United States	Medical Oncology Associates	Spokane	Washington
United States	Highlands Oncology Group	Springdale	Arkansas
United States	Hematology and Oncology Associates at Bridgepoint	Tupelo	Mississippi
United States	Kaiser Permanente; Oncology Clinical Trials	Vallejo	California
United States	Kaiser Permanente - Walnut Creek	Walnut Creek	California
United States	Clinical Research Alliance	Westbury	New York

Sponsors (1)

Lead Sponsor	Collaborator
Hoffmann-La Roche

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Austria,  Belgium,  Brazil,  Bulgaria,  Canada,  Chile,  France,  Germany,  Israel,  Italy,  Japan,  Latvia,  Lithuania,  Mexico,  Netherlands,  Peru,  Portugal,  Russian Federation,  Singapore,  Slovakia,  Spain,  Taiwan,  Ukraine, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population	PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the ITT population.	Up to approximately 30 months after first participant enrolled
Primary	Overall Survival (OS) in the ITT Population	OS is defined as the time between the date of randomization and date of death from any cause in the ITT population.	Up to approximately 39 months after first participant enrolled
Secondary	OS in the in the Teff Population	OS is defined as the time between the date of randomization and date of death from any cause in the in the Teff Population.	Up to approximately 39 months after first participant enrolled
Secondary	PFS as Determined by the Investigator Using RECIST v1.1 in the Teff Population	PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the Teff Population.	Up to approximately 30 months after first participant enrolled
Secondary	PFS as Determined by the Investigator Using RECIST v1.1 in the Tumor Cell (TC) 2/3 or Tumor-Infiltrating Immune Cell (IC) 2/3 Population	PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the Tumor Cell (TC) 2/3 or Tumor-Infiltrating Immune Cell (IC) 2/3 Population.	Up to approximately 30 months after first participant enrolled
Secondary	PFS as Determined by the Investigator Using RECIST v1.1 in the TC1/2/3 or IC1/2/3 Population	PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the TC1/2/3 or IC1/2/3 Population.	Up to approximately 30 months after first participant enrolled
Secondary	OS in the TC2/3 or IC2/3 Population	OS is defined as the time between the date of randomization and date of death from any cause, in the TC2/3 or IC2/3 Population.	Up to approximately 39 months after first participant enrolled
Secondary	OS in the TC1/2/3 or IC1/2/3 Population	OS is defined as the time between the date of randomization and date of death from any cause in the TC1/2/3 or IC1/2/3 Population.	Up to approximately 39 months after first participant enrolled
Secondary	Percentage of Participants With Objective Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population	Proportion of participants with an objective response (CR or PR) in the ITT population.	Up to approximately 30 months after first participant enrolled
Secondary	Duration of Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population	Duration of response is defined as the time from the first documented objective response to documented PD or death from any cause, whichever occurred first, in the ITT Population.	Up to approximately 30 months after first participant enrolled
Secondary	Event Free Rate at 1 and 2 Years in the ITT Population	Event free rate at 1 and 2 years is defined as the proportion of participants alive at 1 and 2 years after randomization estimated using Kaplan-Meier (KM) methodology for the ITT population.	1 and 2 years
Secondary	Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-C30 Symptom Subscales in the ITT Population	TTD in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-C30 Symptom Subscales in the ITT Population. The EORTC QLQ-C30 is a validated and reliable self-report measure that consists of 30 questions that assess five aspects of patient functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, pain), global health/quality of life, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). EORTC scales and single-item measures will be linearly transformed so that each score has a range of 0-100. A high score for a functional scale represents a high or healthy level of functioning, and a high score for the global health status and HRQoL represents a high HRQoL; however, a high score for a symptom scale or item represents a high level of symptomatology or problems.	Up to approximately 30 months after first participant enrolled
Secondary	TTD in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-LC13 Symptom Subscales in the ITT Population	TTD was documented for a 3-symptom composite endpoint using the following EORTC QLQ-LC13 symptom scores: cough, chest pain, and dyspnea multi--item scale. In this instance, symptom deterioration will be determined as a >= 10-point increase above baseline in any of the listed symptom scores, whichever occurs first (cough, chest pain, and dyspnea multi-item scale). Confirmed clinically meaningful symptom deterioration will need to be held for the original symptom; a >= 10-point increase above baseline in a symptom score must be held for at least two consecutive assessments or an initial>=10-point increase above baseline followed by death within 3 weeks from the last assessment. A >= 10-point change in the EORTC scale score is perceived by patients as clinically significant.	Up to approximately 30 months after the first participant enrolled
Secondary	Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population	Change from baseline per SILC scale will be analyzed for each lung cancer symptoms scores. SILC questionnaire comprises 3 individual symptoms & are scored at individual symptom level, thus have a dyspnea score, chest pain score, & cough score. There are a total of 9 questions in SILC questionnaire, each question has a minimum value of 0 & maximum value of 4. Each individual symptom score is calculated as average of responses for symptom items. 'Chest pain' score is mean of question 1 & 2, 'Cough' score is mean of question 3 & 4 and 'Dyspnea' score is mean of question 5 to 9 in SILC questionnaire. An increase in score is suggestive of a worsening in symptomology. A score change of =0.3 points for dyspnea & cough symptom scores is considered to be clinically significant; whereas a score change of =0.5 points for chest pain score is considered to be clinically significant. (Note: PD=progression of disease)	Baseline up to approximately 30 months after first participant enrolled
Secondary	PFS as Determined by the Investigator Using RECIST v1.1 in the ITT Population (Arm A and Arm B)	PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the ITT Population Arm A and Arm B.	Up to approximately 30 months after first participant enrolled
Secondary	OS in the ITT Population (Arm A and Arm B)	OS is defined as the time between the date of randomization and date of death from any cause in the ITT Population, Arm A and Arm B.	Up to approximately 39 months after first participant enrolled
Secondary	Percentage of Participants With Adverse Events	Percentage of participants with at least one adverse event.	Up to approximately 68 months after first participant enrolled
Secondary	Percentage of Participants With Anti-therapeutic Antibody (ATA) Response to Atezolizumab	Percentage of participants with Anti-therapeutic Antibody (ATA) response to atezolizumab.	Up to approximately 30 months after first participant enrolled
Secondary	Maximum Observed Serum Atezolizumab Concentration (Cmax)	Maximum observed serum atezolizumab concentration (Cmax). The predose samples will be collected on the same day of treatment administration. The infusion duration of atezolizumab will be of 30-60 minutes.	Cycle 1 Day 1 and Cycle 3 Day 1 (Cycle length = 21 days)
Secondary	Minimum Observed Serum Atezolizumab Concentration (Cmin)	Minimum observed serum atezolizumab concentration (Cmin). The predose samples will be collected on the same day of treatment administration.	Predose on Day 1 of Cycles 1-4, 8, 16, every 8 cycle thereafter (up to 30 months), at treatment discontinuation (up to 30 months), and at 120 days after the last dose of atezolizumab (up to approximately 30 months, each cycle is 21 days)
Secondary	Plasma Concentrations for Paclitaxel	Plasma concentrations for paclitaxel.	Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 180 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days)
Secondary	Plasma Concentrations for Nab-Paclitaxel	Plasma concentrations for nab-paclitaxel.	Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 30 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days)
Secondary	Plasma Concentrations for Carboplatin	Plasma concentrations for carboplatin.	Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 15 to 30 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days)